14 terminated. 14 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 14 | Terminated 14 |
| Phase 1 | 4 | Terminated 4 |
Follow Chronic Myeloid Leukemia: new trials by email Literature Review of Chronic Myeloid Leukemia trials Research Report on Chronic Myeloid Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Full Treatment-free Remission in Patients With Chronic Myeloid Leukemia Nilotinib, Asciminib - Chronic Myeloid Leukemia | Phase 2 | Terminated | Novartis Pharmaceuticals | 135 | 2019-03-22 | 2026-07-13 |
| Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia Dasatinib, Imatinib Mesylate, Nilotinib - Chronic Myelogenous Leukemia, Chronic Myeloid Leukemia | Phase 2 | Terminated | Emory University | 7 | 2016-10-01 | 2018-11-02 |
| Activity and Risk Profile of Ponatinib in Chronic Phase Patients With Chronic Myeloid Leukemia Resistant to Imatinib Ponatinib - Chronic Myeloid Leukemia, Chronic Phase | Phase 2 | Terminated | Gruppo Italiano Malattie EMatologiche dell'Adulto | 14 | 2016-06-23 | 2025-01-17 |
| A Study to Evaluate the Pharmacokinetics, Safety,and Efficacy of Omacetaxine Given Subcutaneously as a Fixed Dose in Patients With Chronic Phase (CP) or Accelerated Phase (AP) Chronic Myeloid Leukemia (CML) (Referred to as the SYNSINCT Study) Omacetaxine mepesuccinate - Chronic Myeloid Leukemia | Phase 1 / Phase 2 | Terminated | Teva Branded Pharmaceutical Products R&D, Inc. | 10 | 2014-10-09 | 2021-11-09 |
| Nilotinib Plus Pegylated Interferon-α2b in CML Nilotinib, Pegylated interferon α-2b - Chronic Myeloid Leukemia | Phase 2 | Terminated | Amsterdam UMC, location VUmc | 20 | 2013-04-01 | 2018-10-12 |
| Efficacy and Safety Study of Dasatinib in Patients With Chronic Myeloid Leukemia Dasatinib (Sprycel) - Chronic Myeloid Leukemia | Phase 2 | Terminated | European Society for Blood and Marrow Transplantation | 50 | 2010-02-01 | 2011-12-07 |
| T-cell Depleted Alternative Donor Transplantation CliniMACS® (T cell depletion) - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 2 | Terminated | Wake Forest University Health Sciences | 53 | 2009-08-01 | 2022-04-22 |
| Bendamustine in Acute Leukemia and MDS Bendamustine - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 27 | 2008-11-01 | 2012-12-04 |
| Imatinib or Nilotinib With Pegylated Interferon-α2b in Chronic Myeloid Leukemia PEG-IFN-a2b - Chronic Myeloid Leukemia | Phase 2 | Terminated | University of Michigan Rogel Cancer Center | 12 | 2007-09-01 | 2023-01-25 |
| Phase 2 Haplotype Mismatched HSCT in Patients With Hematological Malignancies Total Body Irradiation, Thiotepa, Fludarabine - Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | Phase 2 | Terminated | Sherif S. Farag | 9 | 2007-08-07 | 2018-04-10 |
| Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias AT9283 - Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Terminated | Astex Pharmaceuticals, Inc. | 48 | 2006-09-01 | 2024-08-02 |
| Reduced Intensity AlloSCT in(CML) With Persistent Disease Reduced Intensity Conditioning, Busulfan and Fludarabine - Chronic Myeloid Leukemia | Phase 2 | Terminated | Columbia University | 5 | 2003-01-01 | 2011-04-14 |
| Safety and Efficacy of Imatinib in Combination With High Dose Chemotherapy for Acute Phase Chronic Myelogenous Patients Imatinib mesylate 600 mg, Cytarabine, Daunorubicine - Chronic Myeloid Leukemia | Phase 1 / Phase 2 | Terminated | Poitiers University Hospital | 30 | 2001-05-01 | 2005-11-28 |
| Study of the Combination of a Tyrosine Kinase Inhibitor (STI571) and a Pegylated Human Recombinant Interferon alfa2b (PEGINTRON) STI571 and PEG INTRON - Chronic Myeloid Leukemia | Phase 2 | Terminated | University of Bologna | 5 | 2001-04-01 | 2007-08-03 |
Leukemia, Myelogenous, Chronic, BCR-ABL Positive (14) · Leukemia, Myeloid, Acute (4) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (4) · Myelodysplastic Syndromes (3) · Leukemia (2) · Anemia, Refractory, with Excess of Blasts (1) · Bone Marrow Failure Disorders (1) · Hemoglobinopathies (1) · Immunologic Deficiency Syndromes (1) · Leukemia, Myeloid, Chronic-Phase (1) · Lymphoma (1) · Osteopetrosis (1) · Primary Myelofibrosis (1)
Bone Marrow Diseases (14) · Chronic Disease (14) · Disease Attributes (14) · Hematologic Diseases (14) · Hemic and Lymphatic Diseases (14) · Leukemia, Myeloid (14) · Myeloproliferative Disorders (14) · Neoplasms (14) · Neoplasms by Histologic Type (14) · Pathologic Processes (14) · Pathological Conditions, Signs and Symptoms (14) · Leukemia (12) · Immune System Diseases (4) · Immunoproliferative Disorders (4) · Leukemia, Lymphoid (4)
Imatinib Mesylate (3) · nilotinib (3) · peginterferon alfa-2b (3) · Dasatinib (2) · fludarabine (2) · 1-cyclopropyl-3-(3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl)urea (1) · Antilymphocyte Serum (1) · Bendamustine Hydrochloride (1) · Busulfan (1) · Cytarabine (1) · Daunorubicin (1) · Fibroblast Growth Factor 7 (1) · Homoharringtonine (1) · Thiotepa (1) · Whole-Body Irradiation (1)
Amsterdam UMC, location VUmc (1) · Astex Pharmaceuticals, Inc. (1) · Columbia University (1) · Emory University (1) · European Society for Blood and Marrow Transplantation (1) · Gruppo Italiano Malattie EMatologiche dell'Adulto (1) · M.D. Anderson Cancer Center (1) · Novartis Pharmaceuticals (1) · Poitiers University Hospital (1) · Sherif S. Farag (1) · Teva Branded Pharmaceutical Products R&D, Inc. (1) · University of Bologna (1) · University of Michigan Rogel Cancer Center (1) · Wake Forest University Health Sciences (1)
United States (8) · France (3) · Italy (2) · Belgium (1) · Denmark (1) · Finland (1) · Germany (1) · Netherlands (1) · Norway (1) · South Korea (1) · Sweden (1) · Switzerland (1) · United Kingdom (1)
Andrew Gilman, MD (1) · Dale L. Bixby, M.D. (1) · Eduardo L Olavarria, Dr (1) · Fausto Castagnetti (1) · Hagop M. Kantarjian, M.D. (1) · Michele Baccarani, MD (1) · Mtchell S Cairo, MD (1) · Sherif Farag, MD/PhD (1) · William Blum, MD (1)
PMID 21145590, PMID 22987312, PMID 24355079, PMID 29296761, PMID 37119314
2008 (1), 2015 (1)